BOZEMAN, Mont., Jan. 22, 2025 /PRNewswire/ — Atrial fibrillation (AF) is the most common abnormal heart rhythm affecting 6 million people in the USA and can cause strokes and heart failure. Conventional treatments are successful but may need to be repeated, have inherent risks, and are…
Tag: AF
Medtronic drives continued momentum with new data and case presentations for Affera™ Mapping and Ablation System and PulseSelect™ at AF Symposium
JANUARY 17, 2025 – Medtronic, a global leader in healthcare technology, today announced new data and case presentations for the company’s pulsed field ablation (PFA) technologies, Affera™ Mapping and Ablation System with Sphere-9™ Catheter and PulseSelect™, to be presented at the […]
Late-breaking data presented at AF Symposium 2025 highlight key Boston Scientific therapies for management of patients with atrial fibrillation
First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed Field Ablation System Sub-analysis from OPTION clinical trial highlights consistent safety and…
Conformal Medical Announces GLACE Study to be Highlighted at AF Symposium
Abstract presentation will feature the first clinical use of the company’s CLAAS® AcuFORM™ Left Atrial Appendage Occlusion (LAAO) Device NASHUA, N.H., Jan. 16, 2025 /PRNewswire/ — Conformal Medical, Inc., today announced that the early results of its GLACE Study will be presented during…
A new paradigm in electrophysiology: Medtronic receives FDA approval of Affera™ Mapping and Ablation System and Sphere-9™ Catheter
First-of-its-kind, all-in-one HD-mapping and dual energy (pulsed field and radiofrequency) ablation catheter Highly anticipated by electrophysiologists for its innovation and demonstrated safety and efficacy as well as improved workflow and short learning curve Now with two pulsed field…
New Data at Heart Rhythm 2023 Suggests that Unipolar Signals May be Used for a More Precise, Accurate Approach to Treating Arrhythmias
Data from three abstracts highlight the potential of an optimized radiofrequency ablation technique for pulmonary vein isolation (PVI) Preservation of raw unipolar signal using BioSig’s PURE EP™ platform guidance enabled real-time tissue-specific feedback when conducting ablation Cleveland, OH and Westport, […]
egnite Announces Portfolio Expansion to Reduce Stroke Risk in Atrial Fibrillation Patients
Expansion leverages a custom module to help health systems identify patients eligible for lifesaving therapy ALISO VIEJO, Calif.–(BUSINESS WIRE)–egnite, Inc., a leading digital health company for cardiovascular care, announces the expansion of its portfolio with the integration of a custom […]
Brainomix Technology Integrated into New UK Atrial Fibrillation Study
The study will assess the role of Huawei’s wearable technology to detect atrial fibrillation in post-stroke patients OXFORD, England, Feb. 22, 2023 /PRNewswire/ — Brainomix has announced its involvement in a new study sponsored by the University of Liverpool focused on post-stroke atrial fibrillation (AF). […]
New AF and Congenital Heart Disease Data on Vektor Medical’s vMap® Presented at the 15th Asia Pacific Heart Rhythm Society Scientific Session
SAN DIEGO–(BUSINESS WIRE)–Vektor Medical, developer of the world’s first technology to rapidly map cardiac arrhythmias using only 12-lead ECG data, today announced it presented new data on its vMap® technology that demonstrated potential utility in patients with adult congenital heart disease […]
egnite, Inc. Expands into Cardiovascular Disease Supported by New Data on the State of Care for Patients with Atrial Fibrillation
Company to focus on improving the quality of care for all cardiovascular patients in the U.S. ALISO VIEJO, Calif.–(BUSINESS WIRE)–On the heels of its landmark valvular heart disease (VHD) prevalence abstract published in Journal of the American College of Cardiology (JACC), egnite, […]